Literature DB >> 16200222

The role of add-back therapy in the United States.

David L Olive1.   

Abstract

Gonadotropin-releasing hormone (GnRH) agonists are effective in reducing pelvic pain due to endometriosis, but they are associated with a number of hypoestrogenic side effects, such as vasomotor symptoms and loss of bone mineral density. Add-back therapy with a progestin or a progestin plus low-dose estrogen helps to reduce the side effects associated with GnRH agonist administration without compromising efficacy. Add-back therapy should be initiated at the same time as the treatment with a GnRH agonist and longer-term therapy beyond 6 months can be considered in patients meeting the appropriate criteria. Copyright 2005 Prous Science

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16200222

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  2 in total

Review 1.  Endometriosis and abdominal myofascial pain in adults and adolescents.

Authors:  John Jarrell
Journal:  Curr Pain Headache Rep       Date:  2011-10

2.  Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women.

Authors:  Shien Zou; Qiqi Long; Shaofen Zhang; Yi Han; Wei Zhang
Journal:  Int J Clin Exp Med       Date:  2012-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.